Coated pellets for oral colon delivery

Journal of Drug Delivery Science and Technology

Volumn 25, Issue February, 2015, Pages 1-15

  Palugan, Luca ^a   Cerea, Matteo ^a   Zema, Lucia ^a   Gazzaniga, Andrea ^a   Maroni, Alessandra ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Coating; Multiple unit formulations; Oral colon delivery; Oral pulsatile release; Pellets

Indexed keywords

4 ETHYL 2 HYDROXYIMINO 5 NITRO 3 HEXENAMIDE; AMINOSALICYLIC ACID; AMYLOSE; BUDESONIDE; BUTYRIC ACID; CHITOSAN; CURCUMIN; DEXAMETHASONE; DICLOFENAC; DILTIAZEM; FLUOROURACIL; FUROSEMIDE; GALACTOMANNAN; IBUPROFEN; INDOMETACIN; MELOXICAM; METOCLOPRAMIDE; METOPROLOL TARTRATE; METRONIDAZOLE; NILVADIPINE; PARACETAMOL; PECTIN; POLYMER; POLYVINYL ACETATE; PREDNISOLONE; PROPRANOLOL; RIBOFLAVIN; STARCH; THEOPHYLLINE; TIAPRIDE;

COLON; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG PELLET; FILM COATING; MEAN RESIDENCE TIME; NONHUMAN; PELLET EXTRUSION; PH; REVIEW; SPHERONIZATION; VISCOSITY;

EID: 84925447606     PISSN: 17732247     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jddst.2014.12.003     Document Type: Review

References (145)

1. I. Ghebbre-Sellassie, Pharmaceutical Pelletization Technology, Marcel Dekker, New York and Base, 1989.
2. J.L.P. Soh, S. Srimanta, P.W.S. Heng, V.C. Liew, Pelletization techniques, in: Encyclopedia of Pharmaceutical Science and Technology, fourth ed., Taylor and Francis, New York, 2013.
3. S.N. Politis, D.M. Rekkas, Pelletization processes for pharmaceutical applications: a patent review, Recent Pat. Drug Deliv. Formul. 5 (2011) 61-78.
4. F. Podczeck, B.E. Jones, Pharmaceutical Capsules, Pharmaceutical Press, London, 2004.
5. D.L. Wise, Handbook of Pharmaceutical Controlled Release Technology, CRC Press, Boca Raton, 2000.
6. M. Grassi, L. Zema, M.E. Sangalli, et al., Modeling of drug release from partially coated matrices made of a high viscosity HPMC, Int. J. Pharm. 276 (2004)107-114.
7. M.E. Sangalli, L. Zema, A. Maroni, et al., Influence of betacydodextrin on the release of poorly soluble drugs from inert and hydrophilic heterogeneous polymeric matrices, Biomaterials 22 (2001) 2647-2651.
8. J.W. McGinity, LA Felton, Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms, Third ed., CRC Press, Boca Raton, 2013.
9. D. Sauer, M. Cerea, J. Dinunzio, J. McGinity, Dry powder coating of pharmaceuticals: a review, Int. J. Pharm. 457 (2013) 488-502.
10. M. Cerea, L. Zema, L. Palugan, A. Gazzaniga, Recent developments in dry coating, Pharm. Technol. Eur. 20 (2008) 40-44.
11. C. Vecchio, F. Fabiani, M.E. Sangalli, et al., Rotary tangential spray technique for aqueous film coating of indobufen pellets, Drug Dev. Ind. Pharm. 24 (1998) 269-274.
12. A. Gazzaniga, M.E. Sangalli, G. Bruni, et al., The use of β-cyclodextrin as a pelletization agent in the extrusion/spheronization process, Drug Dev. Ind. Pharm. 24 (1998) 869-873.
13. G. Di Pretoro, L. Zema, A. Gazzaniga, et al., Extrusion-spheronisation of highly loaded 5-ASA multiparticulate dosage forms, Int. J. Pharm. 402 (2010) 153-164.
14. G. Di Pretoro, L. Zema, L. Palugan, et al., Optimisation and scale-up of a highly-loaded 5-ASA multi-particulate dosage form using a factorial approach, Eur. J. Pharm. Sci. 45 (2012) 158-168.
15. R. Bianchini, G. Bruni, A. Gazzaniga, C. Vecchio, Influence of extrusion-spheronization processing on the physical properties of d-Indobufen pellets containing pH adjusters, Drug Dev. Ind. Pharm. 18 (1992) 1485-1503.
16. R. Bianchini, G. Bruni, A. Gazzaniga, C. Vecchio, d-Indobufen extended-release pellets prepared by coating with aqueous polymer dispersions, Drug Dev. ind. Pharm. 19 (1993) 2021-2041.
17. A. Gazzaniga, F. Giordano, M.E. Sangalli, L. Zema, Oral colon-specific drug delivery: design strategies, STP Pharma Prat. 4 (1994) 336-343.
18. A. Gazzaniga, A. Maroni, M.E. Sangalli, L. Zema, Time-controlled oral delivery systems for colon targeting, Expert Opin. Drug Deliv. 3 (2006) 583-597.
19. M.M. Patel, A.F. Amin, Recent trends in microbially and/or enzymatically driven colon-specific drug delivery systems, Crit. Rev. Ther. Drug Carr. Syst. 28 (2011) 489-552.
20. A. Rubinstein, Microbially controlled drug delivery to the colon, Biopharm. Drug Dispos. 11 (1990) 465-475.
21. V.R. Sinha, R. Kumria, Microbially triggered drug delivery to the colon, Eur. J. Pharm. Sci. 18 (2003) 3-18.
22. C. Edwards, Physiology of the colorectal barrier, Adv. Drug Deliv. Rev. 28 (1997) 173-190.
23. S.G. Nugent, D. Kumar, D.S. Rampton, D.F. Evans, Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs, Gut 48 (2001) 571-577.
24. C.S. Leopold, D. Eikeler, Eudragit® E as coating material for the pH-controlled drug release in the topical treatment of inflammatory bowel disease (IBD), J. Drug Target 6 (1998) 85-94.
25. S.S. Davis, The design and evaluation of controlled release systems for the gastrointestinal tract, J. Control Release 2 (1985) 27-38.
26. K. Ofori-Kwakye, J.T. Fell, H.L. Sharma, A.M. Smith, Gamma scintigraphic evaluation of film-coated tablets intended for colonic or biphasic release, Int. J. Pharm. 270 (2004) 307-313.
27. V.C. Ibekwe, M.K. Khela, D.F. Evans, A.W. Basit, A new concept in colonic drug targeting: a combined pH-responsive and bacterially-triggered drug delivery technology, Aliment. Pharmacol. Ther. 28 (2008) 911-916.
28. T. Marvola, J. Marvola, H. Kanerva, et al., Neutron activation based gamma scintigraphic evaluation of enteric-coated capsules for local treatment in colon, Int. J. Pharm. 349 (2008) 24-29.
29. H.M. Fadda, E.L. McConnell, M.D. Short, A.W. Basit, Meal-induced acceleration of tablet transit through the human small intestine, Pharm. Res. 26 (2009) 356-360.
30. C.G. Wilson, The transit of dosage forms through the colon, Int. J. Pharm. 395 (2010) 17-25.
31. A. Maroni, L. Zema, M.D. Del Curto, et al., Oral pulsatile delivery: Rationale and chronopharmaceutical formulations, Int. J. Pharm. 398 (2010) 1-8.
32. U. Conte, P. Colombo, A. La Manna, et al., A new Ibuprofen pulsed release oral dosage form, Drug Dev. Ind. Pharm. 15 (1989) 2583-2596.
33. D.R. Friend, New oral delivery systems for treatment of inflammatory bowel disease, Adv. Drug Deliv. Rev. 57 (2005) 247-265.
34. U. Klotz, M. Schwab, Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease, Adv. Drug Deliv. Rev. 57 (2005) 267-279.
35. Y.S.R. Krishnaiah, V. Satyanarayana, B.D. Kumar, R.S. Karthikeyan, Studies on the development of colon-targeted delivery systems for Celecoxib in the prevention of colorectal cancer, J. Drug Target 10 (2002) 247-254.
36. Y.S.R. Krishnaiah, V. Satyanarayana, B.D. Kumar, et al., In vivo pharmacokinetics in human volunteers: oral administered guar gum-based colon-targeted 5-fluorouracil tablets, Eur. J. Pharm. Sci. 19 (2003) 355-362.
37. V.R. Sinha, B.R. Mittal, K.K. Bhutani, R. Kumria, Colonic drug delivery of 5-fluorouracil: an in vitro evaluation, Int. J. Pharm. 269 (2004) 101-108.
38. S. Bourgeois, A. Laham, M. Besnard, et al., In vitro and in vivo evaluation of pectin beads for the colon delivery of β-lactamases, J. Drug Target 13 (2005) 277-284.
39. M. Khoder, N. Tsapis, E. Fattal, Mechanisms of antibiotic resistance and delivery strategies to prevent its emergence, J. Drug Deliv. Sci. Technol. 20 (2010) 407-418.
40. S. Haupt, A. Rubinstein, The colon as a possible target for orally administered peptide and protein drugs, Crit. Rev. Ther. Drug Carr. Syst. 19 (2002) 499-551.
41. S. Bourgeois, R. Harvey, E. Fattal, Polymer colon drug delivery systems and their application to peptides, proteins, and nucleic acids, Am. J. Drug Deliv. 3 (2005) 171-204.
42. A. Maroni, L. Zema, M.D. Del Curto, et al., Oral colon delivery of insulin with the aid of functional adjuvants, Adv. Drug Deliv. Rev. 64 (2012) 540-556.
43. P. Sriamornsak, Application of pectin in oral drug delivery, Expert Opin. Drug Deliv. 8(2011) 1009-1023.
44. S.A. Sande, Pectin-based oral drug delivery to the colon, Expert Opin. Drug Deliv. 2 (2005) 441-450.
45. I.S. Ahmed, Effect of simulated gastrointestinal conditions on drug release from pectin/ethylcellulose as film coating for drug delivery to the colon, Drug Dev. Ind. Pharm. 31 (2005) 465-470.
46. I.S. Ahmed, J.W. Ayres, Comparison of in vitro and in vivo performance of a colonic delivery system, Int. J. Pharm. 409 (2011) 169-177.
47. L.F. Fan, W. He, M. Bai, et al., Biphasic drug release: permeability and swelling of pectin/ethylcellulose films, and in vitro and in vivo correlation of film-coated pellets in dogs, Chem. Pharm. Bull. 56 (2008) 1118-1125.
48. W. He, Q, Du, D.Y. Cao, et al., Study on colon-specific pectin/ethylcellulose film-coated 5-fluorouracil pellets in rats, Int. J. Pharm. 348 (2008) 35-45.
49. W. He, Q, Du, D.Y. Cao, et al., In-vitro and in-vivo studies of pectin/ethylcellulose-film-coated pellets of 5-fluorouracil for colonic targeting, J. Pharm. Pharmacol. 60 (2008) 35-44.
50. A. Bose, A. Elyagoby, T.W. Wong, Oral 5-fluorouracil colon-specific delivery through in vivo pellet coating for colon cancer and aberrant crypt foci treatment, Int. J. Pharm. 468 (2014) 178-186.
51. R. Semdé, K. Amighi, M.J. Devleeschouwer, A.J. Moës, Effect of pectinolytic enzymes on the theophylline release from pellets coated with water insoluble polymers containing pectin HM or calcium pectinate, Int. J. Pharm. 197 (2000) 169-179.
52. R. Semdé, K. Amighi, M.J. Devleeschouwer, A.J. Moës, Studies of pectin HM/ Eudragit® RL/Eudragit® NE film-coating formulations intended for colonic drug delivery, Int. J. Pharm. 197 (2000) 181-192.
53. E. Hagesaether, M. Hiorth, SA Sande, Mucoadhesion and drug permeability of free mixed films of pectin and chitosan: an in vitro and ex vivo study, Eur. J. Pharm. Biopharm. 71 (2009) 325-331.
54. A. Ghaffari, M.R. Avadi, H.R. Moghimi, et al., Mechanistic analysis of drug release from theophylline pellets coated by films containing pectin, chitosan and Eudragit® RS, Drug Dev. Ind. Pharm. 34 (2008) 390-402.
55. M. Hiorth, T. Versland, J. Heikkila, et al., Immersion coating of pellets with calcium pectinate and chitosan, Int. J. Pharm. 308 (2006) 25-32.
56. M. Hiorth, T. Skoien, S.A. Sande, Immersion coating of pellet cores consisting of chitosan and calcium intended for colon drug delivery, Eur. J. Pharm. Biopharm. 75 (2010) 245-253.
57. F. Cui, L. Yang, J. Jin, H. Piao, W. Lin, D. Cun, Preparation and in vitro evaluation of pH, time-based and enzyme-degradable pellets for colonic drug delivery, Drug Dev. Ind. Pharm. 33 (2007) 999-1007.
58. R. Sureshkumar, Munikumar, G.N.K. Ganesh, et al., Formulation and evaluation of pectin-hydroxypropyl methylcellulose coated curcumin pellets for colon delivery, Asian J. Pharm. 3 (2009) 138-142.
59. A. Gulbake, S.K. Jain, Chitosan: a potential polymer for colon-specific drug delivery system, Expert Opin. Drug Deliv. 9 (2012) 713-729.
60. N. Shimono, T. Takatori, M. Ueda, et al., Multiparticulate chitosan-dispersed system for drug delivery, Chem. Pharm. Bull. 51 (2003) 620-624.
61. K. Kaur, K. Kim, Studies of chitosan/organic acid/Eudragit® RS/RL-coated system for colonic delivery, Int. J. Pharm. 366 (2009) 140-148.
62. W. He, L.F. Fan, M. Bai, et al., Chitosan/Kollicoat SR 30D film-coated pellets of aminosalicylates for colonic drug delivery, J. Pharm. Sci. 99 (2010) 186-195.
63. W.S. Omwancha, R. Mallipeddi, B.L. Valle, S.H. Neau, Chitosan as a pore former in coated beads for colon specific drug delivery of 5-ASA, Int. J. Pharm. 441 (2013) 343-351.
64. M. Rabišková, T. Bautzová, J. Gajdziok, et al., Coated chitosan pellets containing rutin intended for the treatment of inflammatory bowel disease: In vitro characteristics and in vivo evaluation, Int. J. Pharm. 422 (2012) 151-159.
65. C. Ji, H. Xu, W. Wu, In vitro evaluation and pharmacokinetics in dogs of guar gum and Eudragit FS30D-coated colon-targeted pellets of indomethacin, J. Drug Target 15 (2007) 123-131.
66. C.M. Ji, H.N. Xu, W. Wu, Guar gum as potential film coating material for colon-specific delivery of fluorouracil, J. Biomater. Appl. 23 (2009) 311-329.
67. J. Varshosaz, J. Emami, N. Tavakoli, et al., Development and evaluation of a novel pellet-based tablet system for potential colon delivery of budesonide. J. Drug Deliv. (2012), http://dx.doi.org/10.1155/2012/905191. Article ID 905191.
68. S. Milojevic, J.M. Newton, J.H. Cummings, et al., Amylose, the new perspective in oral drug delivery to the human large intestine, STP Pharma Sci. 5 (1995) 47-53.
69. S. Milojevic, J.M. Newton, J.H. Cummings, et al., Amylose as a coating for drug delivery to the colon: preparation and in vitro evaluation using glucose pellets, J. Control Release 38 (1996) 85-94.
70. S. Milojevic, J.M. Newton, J.H. Cummings, et al., Amylose as a coating for drug delivery to the colon: preparation and in vitro evaluation using 5-aminosalicylic acid pellets, J. Control Release 38 (1996) 75-84.
71. J.H. Cummings, S. Milojevic, M. Harding, et al., In vivo studies of amylose- and ethylcellulose-coated [13C]glucose microspheres as a model for drug delivery to the colon, J. Control Release 40 (1996) 123-131.
72. L.F. Siew, A.W. Basit, J.M. Newton, The potential of organic-based amylose-ethylcellulose film coatings as oral colon-specific drug delivery systems, AAPS PharmSciTech 1 (2000) 53-61.
73. L.F. Siew, A.W. Basit, J.M. Newton, The properties of amylose-ethylcellulose films cast from organic-based solvents as potential coatings for colonic drug delivery, Eur. J. Pharm. Sci. 11 (2000) 133-139.
74. E.L. McConnell, M.D. Short, A.W. Basit, An in vivo comparison of intestinal pH and bacteria as physiological trigger mechanisms for colonic targeting in man, J. Control Release 130 (2008) 154-160.
75. A.W. Basit, M.D. Short, E.L. McConnell, Microbiota-triggered colonic delivery: robustness of the polysaccharide approach in the fed state in man, J. Drug Target 17 (2009) 64-71.
76. E.L. McConnell, H.M. Fadda, A.W. Basit, Gut instincts: Explorations in intestinal physiology and drug delivery, Int. J. Pharm. 364 (2008) 213-226.
77. C.A. Freire, C.C. Fertig, F. Podczeck, et al., Starch-based coatings for colon-specific drug delivery. Part I: the influence of heat treatment on the physico-chemical properties of high amylose maize starches, Eur. J. Pharm. Biopharm. 72 (2009) 574-586.
78. C. Freire, F. Podczeck, F. Veiga, J. Sousa, Starch-based coatings for colon-specific delivery. Part II: physicochemical properties and in vitro drug release from high amylose maize starch films, Eur. J. Pharm. Biopharm. 72 (2009) 587-594.
79. C. Freire, F. Podczeck, F. Veiga, J. Sousa, Influence of the coating formulation on enzymatic digestibility and drug release from 5-aminosalicylic acid pellets coated with mixtures of high-amylose starch and Surelease® intended for colon-specific drug delivery high-amylose starch-based coatings for colonic delivery. Drug Dev. Ind. Pharm. 36 (2010) 161-172.
80. C. Freire, F. Podczeck, D. Ferreira, et al., Assessment of the in-vivo drug release from pellets film-coated with a dispersion of high amylose starch and ethylcellulose for potential colon delivery, J. Pharm. Pharmacol. 62 (2010) 55-61.
81. Y. Karrout, C. Neut, D. Wils, et al., Colon targeting with bacteria-sensitive films adapted to the disease state, Eur. J. Pharm. Biopharm. 73 (2009) 74-81.
82. Y. Karrout, C. Neut, D. Wils, et al., Characterization of ethylcellulose: starch-based film coatings for colon targeting, Drug Dev. Ind. Pharm. 35 (2009) 1190-1200.
83. Y. Karrout, C. Neut, D. Wils, et al., Novel polymeric film coatings for colon targeting: How to adjust desired membrane properties, Int. J. Pharm. 371 (2009) 64-70.
84. Y. Karrout, C. Neut, D. Wils, et al., Novel polymeric film coatings for colon targeting: drug release from coated pellets, Eur. J. Pharm. Sci. 37 (2009) 427-433.
85. Y. Karrout, C. Neut, F. Siepmann, et al., Enzymatically degraded Eurylon 6 HP-PG: ethylcellulose film coatings for colon targeting in inflammatory bowel disease patients, J. Pharm. Pharmacol. 62 (2010) 1676-1684.
86. Y. Karrout, C. Neut, D. Wils, et al., Enzymatically activated coated multiparticulates containing theophylline for colon targeting, J. Drug Deliv. Sci. Technol. 20 (2010) 193-199.
87. Y. Karrout, C. Neut, D. Wils, et al., Peas starch-based film coatings for site-specific drug delivery to the colon, J. Appl. Polym. Sci. 119 (2011) 1176-1184.
88. H. Pu, L. Chen, X. Li, et al., An oral colon-targeting controlled release system based on resistant starch acetate: Synthetization, characterization, and preparation of film-coating pellets, J. Agric. Food Chem. 59 (2011) 5738-5745.
89. M. Roldo, E. Barbu, J.F. Brown, et al., Azo compounds in colon-specific drug delivery, Expert Opin. Drug Deliv. 4 (2007) 547-560.
90. M. Saffran, G.S. Kumar, C. Savariar, A new approach to the oral administration of insulin and other peptide drugs, Science 233 (1986) 1081-1084.
91. Y. Kimura, Y. Makita, T. Kumagai, et al., Degradation of azo-containing polyurethane by the action of intestinal flora: its mechanism and application as a drug delivery system, Polymer 33 (1992) 5294-5299.
92. T. Yamaoka, Y. Makita, H. Sasatani, et al., Linear type azo-containing polyurethane as drug-coating material for colon-specific delivery: Its properties, degradation behavior, and utilization for drug formulation, J. Control Release 66 (2000) 187-197.
93. H. Tozaki, T. Fujita, J. Komoike, et al., Colon-specific delivery of budesonide with azopolymer-coated pellets: therapeutic effects of budesonide with a novel dosage form against 2,4,6-trinitrobenzenesulphonic acid-induced colitis in rats, J. Pharm. Pharmacol. 51 (1999) 257-261.
94. H. Tozaki, J. Nishioka, J. Komoike, et al., Enhanced absorption of insulin and (Asu1,7)eel-calcitonin using novel azopolymer-coated pellets for colon-specific drug delivery, J. Pharm. Sci. 90 (2001) 89-97.
95. M.Y. Hu, MA Peppercorn, MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis. Expert Opin. Pharmacother. 9 (2008) 1049-1058.
96. K. Klokkers-Bethke, W. Fischer, Development of a multiple unit drug delivery system for positioned release in the gastrointestinal tract, J. Control Release 15(1991) 105-112.
97. C. Tuleu, C. Andrieux, C. Cherbuy, et al., Colonic delivery of sodium butyrate via oral route: acrylic coating design of pellets and in vivo evaluation in rats, Methods Find. Exp. Clin. Pharmacol. 23 (2001) 245-253.
98. A. Akhgari, H.A. Garekani, F. Sadeghi, M. Azimaie, Statistical optimization of indomethacin pellets coated with pH-dependent methacrylic polymers for possible colonic drug delivery, Int. J. Pharm. 305 (2005) 22-30.
99. A. Akhgari, F. Sadeghi, H.A. Garekani, Combination of time-dependent and pH-dependent polymethacrylates as a single coating formulation for colonic delivery of indomethacin pellets, Int.J. Pharm. 320 (2006) 137-142.
100. M.C. Chuong, J.M. Christensen, J.W. Ayres, Sustained delivery of intact drug to the colon: mesalamine formulation and temporal gastrointestinal transit analysis, Pharm. Dev. Technol. 14 (2009) 116-125.
101. C. Nguyen, J.M. Christensen, J.W. Ayres, Novel mesalamine-loaded beads in tablets for delayed release of drug to the colon, Pharm. Dev. Technol. 17 (2012) 73-83.
102. M. Xu, M. Sun, H. Qiao, et al., Preparation and evaluation of colon adhesive pellets of 5-aminosalicylic acid, Int. J. Pharm. 468 (2014) 165-171.
103. V.D. Kadam, S.G. Gattani, Development of colon targeted multiparticulate pulsatile drug delivery system for treating nocturnal asthma, Drug Deliv. 17 (2010) 343-351.
104. F. Liu, P. Moreno, A.W. Basit, A novel double-coating approach for improved pH-triggered delivery to the ileo-colonic region of the gastrointestinal tract, Eur. J. Pharm. Biopharm. 74 (2010) 311-315.
105. F.J.O. Varum, F. Veiga, J.S. Sousa, A.W. Basit, Mucoadhesive platforms for targeted delivery to the colon, Int. J. Pharm. 420 (2011) 11-19.
106. M.W. Rudolph, S. Klein, T.E. Beckert, et al., A new 5-aminosalicylic acid multi-unit dosage form for the therapy of ulcerative colitis, Eur. J. Pharm. Biopharm. 51 (2001) 183-190.
107. V.K. Gupta, M.W. Assmus, T.E. Beckert, J.C. Price, A novel pH- and time-based multi-unit potential colonic drug delivery system. II. Optimization of multiple response variables, Int. J. Pharm. 213 (2001) 93-102.
108. V.K. Gupta, T.E. Beckert, J.C. Price, A novel pH- and time-based multi-unit potential colonic drug delivery system. I. Development, Int. J. Pharm. 213 (2001) 83-91.
109. C. Bott, M.W. Rudolph, A.R.J. Schneider, et al., In vivo evaluation of a novel pH- and time-based multiunit colonic drug delivery system, Aliment. Pharmacol. Ther. 20 (2004) 347-353.
110. N.V. Patel, J.K. Patel, S.H. Shah, J.N. Patel, Central composite design for the formulation and optimization of a multi-unit potential colonic drug delivery system of budesonide for ulcerative colitis, Pharmazie 66 (2011) 124-129.
111. S.S. Kulthe, J.K. Bahekar, C.C. Godhani, et al., Modulated release of 5-fluorouracil from pH-sensitive and colon targeted pellets: an industrially feasible approach, Drug Dev. Ind. Pharm. 39 (2013) 138-145.
112. C. Gao, J. Huang, Y. Jiao, et al., In vitro release and in vivo absorption in beagle dogs of meloxicam from Eudragit® FS 30 D-coated pellets, Int. J. Pharm. 322 (2006) 104-112.
113. P.C. Ferrari, F.M. Souza, L. Giorgetti, et al., Development and in vitro evaluation of coated pellets containing chitosan to potential colonic drug delivery, Carbohyd Polym. 91 (2013) 244-252.
114. M. Marvola, P. Nykänen, S. Rautio, et al., Enteric polymers as binders and coating materials in multiple-unit site-specific drug delivery systems, Eur. J. Pharm. Sci. 7 (1999) 259-267.
115. P. Nykänen, K. Krogars, M. Säkkinen, et al., Organic acids as excipients in matrix granules for colon-specific drug delivery, Int. J. Pharm. 184 (1999) 251-261.
116. C.S. Leopold, D. Eikeler, Basic coating polymers for the colon-specific drug delivery in inflammatory bowel disease, Drug Dev. Ind. Pharm. 26 (2000) 1239-1246.
117. J. Varshosaz, J. Emami, N. Tavakoli, et al., Colon specific delivery of budesonide based on triple coated pellets: In vitro/in vivo evaluation, Acta Pharm. 62 (2012) 341-356.
118. A. Maroni, L. Zema, G. Loreti, et al., Film coatings for oral pulsatile release, Int. J. Pharm. 457 (2013) 362-371.
119. A. Maroni, M.D. Del Curto, L. Zema, et al., Film coatings for oral colon delivery, Int. J. Pharm. 457 (2013) 372-394.
120. S. Ueda, T. Hata, S. Asakura, et al., Development of a novel drug release system, time-controlled explosion system (TES): I - concept and design, J. Drug Target 2 (1994) 35-44.
121. S. Ueda, H. Yamaguchi, M. Kotani, et al., Development of a novel drug release system, time-controlled explosion system (TES). II. Design of multiparticulate TES and in vitro drug release properties, Chem. Pharm. Bull. 42 (1994) 359-363.
122. S. Ueda, R. Ibuki, S. Kimura, et al., Development of a novel drug release system, time-controlled explosion system (TES). III. Relation between lag time and membrane thickness, Chem. Pharm. Bull. 42 (1994) 364-367.
123. S. Ueda, R. Ibuki, A. Kawamura, et al., Development of a novel drug delivery system, time-controlled explosion system (TES): IV. In vivo drug release behavior, J. Drug Target 2 (1994) 133-140.
124. T. Hata, Y. Shimazaki, A. Kagayama, et al., Development of a novel drug release system, time-controlled explosion system (TES). V. Animal pharmacodynamic study and human bioavailability study, Int. J. Pharm. 110 (1994) 1-7.
125. S. Murata, S. Ueda, F. Shimojo, et al., In vivo performance of time-controlled explosion system (TES) in GI physiology regulated dogs, Int. J. Pharm. 16 (1998) 161-168.
126. A. Mohamad, A. Dashevsky, Development of pulsatile multiparticulate drug delivery system coated with aqueous dispersion Aquacoat® ECD, Int. J. Pharm. 318 (2006) 124-131.
127. A. Mohamad, A. Dashevsky, In vitro and in vivo performance of a multiparticulate pulsatile drug delivery system, Drug Dev. Ind. Pharm. 33 (2007) 113-119.
128. Y. Liu, S. Liu, Q. Dai, Design and evaluation of pH-independent pulsatile release pellets containing isosorbide-5-mononitrate, Chem. Pharm. Bull. 57 (2009) 55-60.
129. D. Yadav, S. Survase, N. Kumar, Dual coating of swellable and rupturable polymers on Glipizide loaded MCC pellets for pulsatile delivery: formulation design and in vitro evaluation, Int. J. Pharm. 419 (2011) 121-130.
130. P. Schultz, P. Kleinebudde, A new multiparticulate delayed release system. Part I: dissolution properties and release mechanism, J. Control Release 47 (1997) 181-189.
131. P. Schultz, I. Tho, P. Kleinebudde, A new multiparticulate delayed release system. Part II: coating formulation and properties of free films, J. Control Release 47 (1997) 191-199.
132. A. Maroni, M.D. Del Curto, M. Cerea, et al., Polymeric coatings for a multiple-unit pulsatile delivery system: Preliminary study on free and applied films, Int. J. Pharm. 440 (2013) 256-263.
133. M.D. Del Curto, L. Palugan, A. Foppoli, et al., Erodible time-dependent colon delivery systems with improved efficiency in delaying the onset of drug release, J. Pharm. Sci. 103 (2014) 3585-3593.
134. C. Caramella, P. Colombo, U. Conte, et al., The role of swelling in the disintegration process, Int. J. Pharm. Tech. Prod. Manuf. 5 (1984) 1-5.
135. F. Giordano, A. Rossi, R. Bettini, et al., Thermal behavior of paracetamol polymeric excipients mixtures, J. Therm. Anal. Calorim. 68 (2002) 575-590.
136. A. Maroni, M.D. Del Curto, M. Serratoni, et al., Feasibility, stability and release performance of a time-dependent insulin delivery system intended for oral colon release, Eur. J. Pharm. Biopharm. 72 (2009) 246-251.
137. M.D. Del Curto, A. Maroni, A. Foppoli, et al., Preparation and evaluation of an oral delivery system for time-dependent colon release of insulin and selected protease inhibitor and absorption enhancer compounds, J. Pharm. Sci. 98 (2009) 4661-4669.
138. M.D. Del Curto, A. Maroni, L. Palugan, et al., Oral delivery system for two-pulse colonic release of protein drugs and protease inhibitor/absorption enhancer compounds, J. Pharm. Sci. 100 (2011) 3251-3259.
139. S. Narisawa, M. Nagata, C. Danyoshi, et al., An organic acid-induced sigmoidal release system for oral controlled-release preparations, Pharm. Res. 11 (1994) 111-116.
140. S. Narisawa, M. Nagata, T. Ito, et al., Drug release behavior in gastrointestinal tract of beagle dogs from multiple unit type rate-controlled or time-controlled release preparations coated with insoluble polymer-based film, J. Control Release 33 (1995) 253-260.
141. S. Narisawa, M. Nagata, Y. Hirakawa, et al., An organic acid-induced sigmoidal release system for oral controlled- release preparations. 2. Permeability enhancement of Eudragit RS coating led by the physicochemical interactions with organic acid, J. Pharm. Sci. 85 (1996) 184-188.
142. C.C. Kao, S.C. Chen, M.T. Sheu, Lag time method to delay drug release to various sites in the gastrointestinal tract, J. Control Release 44 (1997) 263-270.
143. B. Abrahamsson, M. Alpsten, U.E. Jonsson, et al., Gastro-intestinal transit of a multiple-unit formulation (metoprolol CR/ZOK) and a nondisintegrating tablet with the emphasis on colon, Int. J. Pharm. 140 (1996) 229-235.
144. C. Schiller, C.P. Fröhlich, T. Giessmann, et al., Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging, Aliment. Pharmacol. Ther. 22 (2005) 971-979.
145. F.J.O. Varum, H.A. Merchant, A.W. Basit, Oral modified-release formulations in motion: the relationship between gastrointestinal transit and drug absorption, Int. J. Pharm. 395 (2010) 26-36.